Oncology as On Today Essence of ESMO WCLC 2022 | Welcome & Introduction

IMpower010 : Updated data of phase III Trial of adjuvant Atezolizumab vs BSC in Resected State IB-IIA NSCLC After adjuvant Chemotherapy

Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable lung cancer the INCREASE trial

Oncology as On Today Essence of ESMO WCLC 2022 | Welcome & Introduction

High dimensional Immuno-phenotyping of innmunotherapy response in head and neck cancer

Evaluation of the DNA damage response DDR Network as Predictor of Nivolumab efficany in Head and neck Squamous Cell Carcinoma HNSCC